Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry

Prater, Julia; Valeri, Fabio; Korol, Dimitri; Rohrmann, Sabine; Dehler, Silvia

doi:10.1007/s00432-015-2031-1

Cited by 7 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…reported 10‐year cumulative metachronous CBC risks of approximately 4–5.5% in a large population based sample of over 85.000 women with previous invasive BC without distant metastases in Denmark . A population‐based study performed in Switzerland revealed a CBC incidence rate of approximately 4.5–5 per 1,000 PY after 4–11 years follow‐up, compared to 4.1 per 1.000 PY in our study after 5–10 years follow‐up . These results suggest that the CBC risk in our cohort of BRCA1/2 noncarriers is on average as high as in the general population.…”

Section: Discussioncontrasting

confidence: 47%

“…38 A population-based study performed in Switzerland revealed a CBC incidence rate of approximately 4.5-5 per 1,000 PY after 4-11 years follow-up, compared to 4.1 per 1.000 PY in our study after 5-10 years follow-up. 39 These results suggest that the CBC risk in our cohort of BRCA1/2 noncarriers is on average as high as in the general population. As a consequence, for this group of women and for women from the general population, the same intensity of surveillance measures might be recommended.…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance

Engel

Fischer

Zachariae

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Comparably little is known about breast cancer (BC) risks in women from families tested negative for BRCA1/2 mutations despite an indicative family history, as opposed to BRCA1/2 mutation carriers. We determined the age‐dependent risks of first and contralateral breast cancer (FBC, CBC) both in noncarriers and carriers of BRCA1/2 mutations, who participated in an intensified breast imaging surveillance program. The study was conducted between January 1, 2005, and September 30, 2017, at 12 university centers of the German Consortium for Hereditary Breast and Ovarian Cancer. Two cohorts were prospectively followed up for incident FBC (n = 4,380; 16,398 person‐years [PY], median baseline age: 39 years) and CBC (n = 2,993; 10,090 PY, median baseline age: 42 years). Cumulative FBC risk at age 60 was 61.8% (95% CI 52.8–70.9%) for BRCA1 mutation carriers, 43.2% (95% CI 32.1–56.3%) for BRCA2 mutation carriers and 15.7% (95% CI 11.9–20.4%) for noncarriers. FBC risks were significantly higher than in the general population, with incidence rate ratios of 23.9 (95% CI 18.9–29.8) for BRCA1 mutation carriers, 13.5 (95% CI 9.2–19.1) for BRCA2 mutation carriers and 4.9 (95% CI 3.8–6.3) for BRCA1/2 noncarriers. Cumulative CBC risk 10 years after FBC was 25.1% (95% CI 19.6–31.9%) for BRCA1 mutation carriers, 6.6% (95% CI 3.4–12.5%) for BRCA2 mutation carriers and 3.6% (95% CI 2.2–5.7%) for noncarriers. CBC risk in noncarriers was similar to women with unilateral BC from the general population. Further studies are needed to confirm whether less intensified surveillance is justified in women from BRCA1/2 negative families with elevated risk.

show abstract

Section: Discussioncontrasting

confidence: 47%

Section: Discussionmentioning

confidence: 55%

Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance

Engel

Fischer

Zachariae

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…This very efficient method is rarely used to establish drug-drug interaction in cancer-related studies. Instead, usually simple-type associations between tested compounds are presented, where only one or few random chosen doses are selected, without precise method of drug-type interaction analysis [ 53 , 55 – 57 ].…”

Section: Discussionmentioning

confidence: 99%

Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines – An Isobolographic Analysis

et al. 2015

View full text Add to dashboard Cite

Histone deacetylase inhibitors (HDIs) are promising anticancer drugs, which inhibit proliferation of a wide variety of cancer cells including breast carcinoma cells. In the present study, we investigated the influence of valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA, vorinostat), alone or in combination with cisplatin (CDDP) on proliferation, induction of apoptosis and cell cycle progression in MCF7, T47D and MDA-MB-231 human breast carcinoma cell lines. The type of interaction between HDIs and CDDP was determined by an isobolographic analysis. The isobolographic analysis is a very precise and rigorous pharmacodynamic method, to determine the presence of synergism, addition or antagonism between different drugs with using variety of fixed dose ratios. Our experiments show that the combinations of CDDP with SAHA or VPA at a fixed-ratio of 1:1 exerted additive interaction in the viability of MCF7 cells, while in T47D cells there was a tendency to synergy. In contrast, sub-additive (antagonistic) interaction was observed for the combination of CDDP with VPA in MDA-MB-231 “triple-negative” (i.e. estrogen receptor negative, progesterone receptor negative, and HER-2 negative) human breast cancer cells, whereas combination of CDDP with SAHA in the same MDA-MB-231 cell line yielded additive interaction. Additionally, combined HDIs/CDDP treatment resulted in increase in apoptosis and cell cycle arrest in all tested breast cancer cell lines in comparison with a single therapy. In conclusion, the additive interaction of CDDP with SAHA or VPA suggests that HDIs could be combined with CDDP in order to optimize treatment regimen in some human breast cancers.

show abstract

“…This is especially important since, according to the existing literature, between 1.9% and 11.1% of women will have an ipsilateral breast cancer recurrence (median follow‐up 10.5 years) and between 1.1% and 8.3% of women will have contralateral breast cancer (median follow‐up 7.5 years) 16 . Our group has previously shown that of 16 323 patients with unilateral primary breast cancer diagnosed in the canton of Zurich between 1980 and 2006, 700 (4.3%) developed a second malignant tumor of the opposite breast 17 …”

Section: Introductionmentioning

confidence: 94%

“…16 Our group has previously shown that of 16 323 patients with unilateral primary breast cancer diagnosed in the canton of Zurich between 1980 and 2006, 700 (4.3%) developed a second malignant tumor of the opposite breast. 17 In this study, we aimed to identify important key characteristics for the prediction of a malignant SBC from readily available patient-level data and classify the patients as high or low risk for SBC. The small percentage of cases that need to be detected makes the data imbalanced, an aspect that together with missing values in potentially crucial predictors, is often neglected in the literature.…”

Section: Introductionmentioning

confidence: 99%

Predicting second breast cancer among women with primary breast cancer using machine learning algorithms, a population‐based observational study

Syleouni

Karavasiloglou

Manduchi

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

Breast cancer survivors often experience recurrence or a second primary cancer. We developed an automated approach to predict the occurrence of any second breast cancer (SBC) using patient‐level data and explored the generalizability of the models with an external validation data source. Breast cancer patients from the cancer registry of Zurich, Zug, Schaffhausen, Schwyz (N = 3213; training dataset) and the cancer registry of Ticino (N = 1073; external validation dataset), diagnosed between 2010 and 2018, were used for model training and validation, respectively. Machine learning (ML) methods, namely a feed‐forward neural network (ANN), logistic regression, and extreme gradient boosting (XGB) were employed for classification. The best‐performing model was selected based on the receiver operating characteristic (ROC) curve. Key characteristics contributing to a high SBC risk were identified. SBC was diagnosed in 6% of all cases. The most important features for SBC prediction were age at incidence, year of birth, stage, and extent of the pathological primary tumor. The ANN model had the highest area under the ROC curve with 0.78 (95% confidence interval [CI] 0.750.82) in the training data and 0.70 (95% CI 0.61‐0.79) in the external validation data. Investigating the generalizability of different ML algorithms, we found that the ANN generalized better than the other models on the external validation data. This research is a first step towards the development of an automated tool that could assist clinicians in the identification of women at high risk of developing an SBC and potentially preventing it.

show abstract

Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry

Cited by 7 publications

References 35 publications

Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance

Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance

Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines – An Isobolographic Analysis

Predicting second breast cancer among women with primary breast cancer using machine learning algorithms, a population‐based observational study

Contact Info

Product

Resources

About